Rubicon Research Limited IPO Review
Neutral461-485 · Mainboard
✦
Analyst Verdict
Rubicon Research Limited IPO
Neutral
IPO at a Glance
Price Band
461-485
Issue Size
1378cr
Min. Investment
₹14,550
Opens
2025-10-07
Closes
2025-10-11
Listing
2025-10-14
Category
Mainboard
Key Strengths
✓Holds a strong portfolio of commercialised products, maintaining a market share of over 25% for seven products in the US market.
✓R&D capabilities in India and Canada enable product innovation and development, reducing reliance on third parties.
✓Established US sales and distribution platform through subsidiaries, covering both non-branded and branded product markets.
✓Demonstrates regulatory compliance with US FDA inspections and approvals from international bodies.
Key Risks
⚠The company heavily relies on the US market, making it vulnerable to adverse developments in that region.
⚠Operating in a highly regulated industry, any product recalls, inspection failures, or facility shutdowns could negatively impact operations.
⚠R&D efforts may not always lead to successful marketable products, posing risks to revenue growth.
⚠Intense competition within the pharmaceutical industry may affect margins and hinder future growth prospects.
⚠Fluctuations in foreign currency exchange rates could negatively impact the company’s financial performance.
⚠Debt agreements, including unsecured loans, impose restrictive covenants, and any non-compliance could lead to accelerated repayment obligations.
Frequently Asked Questions
Should I apply for Rubicon Research Limited IPO?
Based on our analysis, our rating for Rubicon Research Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Rubicon Research Limited IPO?
The company heavily relies on the US market, making it vulnerable to adverse developments in that region. Operating in a highly regulated industry, any product recalls, inspection failures, or facility shutdowns could negatively impact operations. R&D efforts may not always lead to successful marketable products, posing risks to revenue growth.
What are the strengths of Rubicon Research Limited IPO?
Holds a strong portfolio of commercialised products, maintaining a market share of over 25% for seven products in the US market. R&D capabilities in India and Canada enable product innovation and development, reducing reliance on third parties. Established US sales and distribution platform through subsidiaries, covering both non-branded and branded product markets.
What is the price band of Rubicon Research Limited IPO?
The price band for Rubicon Research Limited IPO is 461-485. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more